Efficacy of topical application of etamsylate in herpes simplex labialis


Efficacy of topical application of etamsylate in herpes simplex labialis


Pedro Cuevas1, Javier Angulo2 Guillermo Giménez-Gallego3

1Universidad Alfonso X el Sabio, Madrid, 2Servicio de Histología, Departamento de Investigación, Hospital Universitario Ramón y Cajal, Madrid, 3Departamento de Estructura y Función de Proteínas, Centro de Investigaciones Biológicas, Madrid, Spain.


International-Journal-of-Case-Reports-2d code

Herpes simplex virus type-1 (HSV-1) causes a wide variety of clinical disorders of major public health concern. HSV-1 infections are common in oral and perioral area. We report the short-term efficacy of topical application of etamsylate in herpes simplex labialis lesion. Mucosal lesion resolved after 4 days of treatment leaving behind no apparent signs of cosmetic disturbance.


Keywords: Herpes simplex virus type-1. Etamsylate. Topical application. Fibroblast growth factor


Free Full-text PDF


How to cite this article:
Pedro Cuevas, Javier Angulo Guillermo Giménez-Gallego.Efficacy of topical application of etamsylate in herpes simplex labialis. International Journal of Case Reports, 2018 2:28. DOI: 10.28933/ijcr-2018-05-2902.


References:

1. Wald A, Corey L. In: Human Herpes viruses; Biology, Therapy and Immunoprophylaxis. Cambridge. Cambridge University Press, 2007.
2. Sciubba JJ. Herpes simplex and aphthous ulcerations: presentation, diagnosis and management–an update. Gen Dent. 2003;51(6):510-6.
3. Chi CC1, Wang SH, Delamere FM, Wojnarowska F, Peters MC, Kanjirath PP. Interventions for prevention of herpes simplex labialis (cold sores on the lips). Cochrane Database Syst Rev. 2015;7;(8):CD010095. doi: 10.1002/14651858. CD010095.pub2.
4. Spruance SL. The natural history of recurrent oral-facial herpes simplex virus infection. Semin Dermatol. 1992;11(3):200-6.
5. Huff JC, Krueger GG, Overall JC Jr, Copeland J, Spruance SL. The histopathologic evolution of recurrent herpes simplex labialis. J Am Acad Dermatol. 1981;5(5):550-7.
6. Cunningham AL, Diefenbach RJ, Miranda-Saksena M, Bosnjak L, Kim M, Jones C, Douglas MW. The cycle of human herpes simplex virus infection: virus transport and immune control. J Infect Dis. 2006;194 Suppl 1:S11-8.
7. Morfin F, Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol. 2003;26(1):29-37.
8. Spruance SL, Nett R, Marbury T, Wolff R, Johnson J, Spaulding T. Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Antimicrob Agents Chemother. 2002;46(7):2238-43.
9. Fernández IS, Cuevas P, Angulo J, López-Navajas P, Canales-Mayordomo A, González-Corrochano R, Lozano RM, Valverde S, Jiménez-Barbero J, Romero A, Giménez-Gallego G. Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors. J Biol Chem. 2010;285(15):11714-29.
10. Kaner RJ, Baird A, Mansukhani A, Basilico C, Summers BD, Florkiewicz RZ, Hajjar DP. Fibroblast growth factor receptor is a portal of cellular entry for herpes simplex virus type 1. Science. 1990;248(4961):1410-3.
11. Baird A, Florkiewicz RZ, Maher PA, Kaner RJ, Hajjar DP. Mediation of virion penetration into vascular cells by association of basic fibroblast growth factor with herpes simplex virus type 1. Nature. 1990;348(6299):344-6.
12. Gurung HR, Carr MM, Bryant K, Chucair-Elliott AJ, Carr DJ. Fibroblast growth factor-2 drives and maintains progressive corneal neovascularization following HSV-1 infection. Mucosal Immunol. 2018;11(1):172-185. doi: 10.1038/mi.2017.26.
13. Botta M, Manetti F, Corelli F. Fibroblast growth factors and their inhibitors. Curr Pharm Des. 2000;6:1897-924.
14. Aguilar JS, Rice M, Wagner EK. The polysulfonated compound suramin blocks adsorption and lateral difusion of herpes simplex virus type-1 in vero cells. Virology. 1999;258(1):141-51.
15. Angulo J, Cuevas P, Cuevas B, El Youssef M, Fernández A, Martínez-Salamanca E, González-Corrochano R, Giménez-Gallego G.Diacetyloxyl derivatization of the fibroblast growth factor inhibitor dobesilate enhances its anti-inflammatory, anti-angiogenic and anti-tumoral activities. J Transl Med. 2015;13:48. doi: 10.1186/s12967-015-0413-4.
16. Readhead B, Haure-Mirande JV, Funk CC, Richards MA, Shannon P, Haroutunian V, Sano M, Liang WS, Beckmann ND, Price ND, Reiman EM. Multiscale Analysis of Independent Alzheimer’s Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus. Neuron. 2018 pii: S0896-6273(18)30421-5.doi: 10.1016/ j.neuron.2018.05.023.